GLP1R and type 2 diabetes mellitus: In these studies, GLP-1 receptor agonist treatment consistently reduced urinary albumin-to-creatinine ratios (UACRs) by 20%–40% and new-onset macroalbuminuria in people with T2D (12, 13).